FDA-approved BRAF inhibitors that target effectively mutated monomeric BRAF elicit remarkable clinical responses in BRAFV600E mutant melanoma, however, activated BRAF dimers remain poorly targeted, a fact that leads to limited progression free survival in melanoma and other tumors such as colorectal and thyroid with oncogenic BRAF signaling. Our proposal addresses this significant unmet medical need. We propose to use our expertise in drug discovery and unique insights into BRAF structure and regulation, to identify the next- generation BRAF inhibitors with high specificity for BRAFV600E dimers that will ultimately serve as prototype therapeutics.
|Effective start/end date||12/1/19 → 11/30/22|
- National Cancer Institute: $860,507.00
- National Cancer Institute: $405,903.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.